The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.

Moderate to severe atopic dermatitis (AD) can be debilitating and often requires use of systemic immunosuppressant therapy to achieve adequate disease control. There are currently no US Food and Drug Administration-approved systemic agents for the long-term treatment of AD. Recent insight has identified the T helper 2 cytokines, interleukins 4 and 13, as playing a major role in the pathogenesis of AD. There are multiple novel biologic agents in development that target interleukins 4 and/or 13 for the treatment of moderate to severe AD. The age of targeted biologics for AD has arrived.

Silverberg JI ，Kantor R 《-》

Biologics for Atopic Dermatitis.

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that has become a global health problem. The pathophysiology of AD includes both skin barrier and immune abnormalities, with type 2 immune deviation central to several clinical phenotypes and underlying endotypes. Recognition of the persistent nature and systemic aspects of AD provides a rationale for treatment with a biologic. Dupilumab has been approved for patients 6 years of age and older with moderate to severe AD. Monoclonal antibodies are in phase 3 trials and may become part of a precision medicine approach to AD.

Boguniewicz M 《-》

IL-4 and IL-13 Inhibition in Atopic Dermatitis.

Matsunaga MC ，Yamauchi PS 《Journal of Drugs in Dermatology》

Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.

D'Erme AM ，Romanelli M ，Chiricozzi A 《Drug Design Development and Therapy》

Dupilumab for the treatment of adolescents with atopic dermatitis.

Senner S ，Seegräber M ，Frey S ，Kendziora B ，Eicher L ，Wollenberg A ... -  《-》